Drug intelligence / Profile preview

Naoxinshu oral liquid

Development stage: Unknown
Lead developer: Shenhua Pharmaceutical
Administration: Oral

Overview

Naoxinshu oral liquid is a traditional Chinese medicine (TCM) formulation marketed by Shenhua Pharmaceutical and numerous other manufacturers in China. The preparation typically consists of extracts from *Armillaria mellea* (honey mushroom), honey, and royal jelly. It is characterized by its nourishing, tranquilizing, and sedative properties. Clinically, it is indicated for the treatment of neurasthenia, insomnia, dreaminess, dizziness, and headaches. It is also used to manage symptoms related to poor cardiovascular and cerebrovascular blood circulation, such as those found in coronary heart disease. The drug is administered orally as a liquid solution.

Brand names: 脑心舒口服液
Other names: Naoxinshu脑心舒

Beyond the preview

Go deeper on Naoxinshu oral liquid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naoxinshu oral liquid.

Explore the full profile